Pacific Edge (NZE:PEB, ASX:PEB) said its product Cxbladder Triage has been included by the American Urological Association as the standard of care in an amendment to its clinical guideline for microhematuria patients, according to a Friday filing with the Australian and New Zealand bourses.
The guideline mentions the product as the only urine-based biomarker test that has "Grade A" evidence from a randomized controlled trial in support of this recommendation, the filing said.
Company shares rose 5% in recent Monday trade in New Zealand and jumped almost 22% in Australia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.